HOME >> BIOLOGY >> NEWS
Fauci: New Findings Help Explain "Rebound" Of HIV In Patients Who Discontinue Triple-Drug Therapy

esent his laboratory's new observations at the 5th Conference on Retroviruses and Opportunistic Infections in Chicago, Ill., on Wednesday, February 4 at 6:30 p.m. in the Sheraton Chicago Ballroom. The lecture is part of a special symposium chaired by Dr. Fauci called "Host Factors in HIV Infection: Implications for Therapy." The symposium also features Drs. Stephen O'Brien of the National Cancer Institute, Barton Haynes of the Duke University School of Medicine, and Giuseppe Pantaleo of Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland.

When an HIV-infected patient is taking HAART, inductive cytokines and other factors which can boost HIV production are still present in their lymph nodes and related organs. However, the powerful effects of HAART nonetheless can reduce viral replication dramatically, sometimes to the point where HIV can be found only in a latent form in resting CD4+ T cells. The new data suggest that when HAART is withdrawn, the effects of HIV-inducing cytokines and other factors once again promote the active production of virus.

"The findings underscore the risks involved in discontinuing antiretroviral therapy, even if a patient feels better and has a viral load that is 'undetectable' using standard assays," Dr. Fauci says. "Our data also stress the importance of developing comprehensive treatment strategies which not only block HIV replication but also modulate the host factors that drive such replication.

Background

In studies dating back to the mid-1980s, Dr. Fauci and his team have shown that certain cytokines normally secreted by immune cells, particularly in the lymph nodes, can boost the replication of HIV. Blocking these so c
'"/>

Contact: Greg Folkers
gfolkers@nih.gov
301-496-2263
NIH/National Institute of Allergy and Infectious Diseases
2-Feb-1998


Page: 1 2 3 4

Related biology news :

1. Findings suggest need for new view of p53 cancer proteins interaction with DNA
2. Findings redefine mechanism of action of RNA helicase enzymes
3. Findings of novel nanoproperties in selenium produced by bacteria open new area of exploration
4. Findings could aid efforts to harness nature for making drugs
5. Findings offer clue to how molecule can both stimulate, suppress cell growth
6. Findings offer further understanding about growth and development in young male gymnasts
7. Findings in frog oocytes may help study of chromosome physiology
8. Findings aid understanding of neurodegenerative diseases
9. Findings show exceptional longevity runs in families
10. Findings give insight into how colon cells transform into precancerous polyps
11. Findings conclude sustained caffeine intake negates the benefits of creatine supplements

Post Your Comments:
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is ... been elected Chairman of the Board, to succeed Donald ... CEO, but will continue as a member of the Board.  ... has added to the company over almost twenty years, the ... The Board of Directors has established a Search Committee to ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
Cached News: